Impact of Serotherapy on Immune Reconstitution and Survival Outcomes After Stem Cell Transplantations in Children: Thymoglobulin Versus Alemtuzumab  by Willemsen, Laura et al.
Biol Blood Marrow Transplant 21 (2015) 473e482Biology of Blood and
Marrow Transplantation
journal homepage: www.bbmt.orgImpact of Serotherapy on Immune Reconstitution and Survival
Outcomes After Stem Cell Transplantations in Children:
Thymoglobulin Versus AlemtuzumabLaura Willemsen 1, Cornelia M. Jol-van der Zijde 1,*, Rick Admiraal 1,2,3, Hein Putter 4,
Anja M. Jansen-Hoogendijk 1, Monique M. Ostaijen-ten Dam1, Juul T. Wijnen 5,
Charlotte van Kesteren 2,3, Jacqueline L.M. Waaijer 1, Arjan C. Lankester 1,
Robbert G.M. Bredius 1, Maarten J.D. van Tol 1
1 Pediatric SCT Unit and Laboratory for Immunology, Department of Pediatrics, Leiden University Medical Center, Leiden, The Netherlands
2 Pediatric Blood and Marrow Program, University Medical Center Utrecht, Utrecht, The Netherlands
3Department of Pharmacology, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands
4Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, The Netherlands
5Departments of Clinical Genetics and Human Genetics, Leiden University Medical Center, Leiden, The NetherlandsArticle history:
Received 7 September 2014
Accepted 13 November 2014
Key Words:
Antithymocyte globulin
Alemtuzumab
Hematopoietic stem cell
transplantation
Immune reconstitution
Survival
ChildrenFinancial disclosure: See Acknowle
* Correspondence and reprint r
Pediatric SCT Unit and Laborato
Medical Center, PO Box 9600, 2300
E-mail address: c.m.jol-van_der
http://dx.doi.org/10.1016/j.bbmt.20
1083-8791/ 2015 American Sociea b s t r a c t
The outcome of allogeneic hematopoietic stem cell transplantation (HSCT) is strongly affected by the kinetics
of reconstitution of the immune system. This study compared the effects of antithymocyte globulin (ATG) and
alemtuzumab on various outcome parameters after HSCT. The study cohort consisted of 148 children, with a
median age of 9.6 years (range, .4 to 19.0), who underwent HSCT for malignant and benign hematological
disorders in a single HSCT unit. Conditioning included ATG (n ¼ 110) or alemtuzumab (n ¼ 38). Cox pro-
portional hazard regression analysis showed that alemtuzumab signiﬁcantly delayed the recovery of CD3þ T
cells and CD4þas well as CD8þ T cell subsets (P  .001) and natural killer (NK) cells (P ¼ .008) compared with
ATG. In both ATG- and alemtuzumab-treated patients, shorter drug exposure lead to signiﬁcantly faster
recovery of T cells. Alemtuzumab was associated with lower donor chimerism 3 and 6 months after trans-
plantation and a higher risk of disease relapse (P ¼ .001). The overall survival and event-free survival risks
were signiﬁcantly lower for alemtuzumab-treated patients (P ¼ .020 and P < .001, respectively). Patients who
received alemtuzumab showed a trend to lower risk of acute graft-versus-host disease, more human
adenovirus, and less Epstein-Barr virus reactivations compared with patients who received ATG. These data
indicate that children treated with alemtuzumab as part of the conditioning regimen have a slower T cell and
NK cell reconstitution compared with those treated with ATG, which compromises the overall and event-free
survival. Prolonged length of lympholytic drug exposure delayed the T cell recovery in both ATG-
and alemtuzumab-treated patients. Therefore, we recommend detailed pharmacokinetic/pharmacodynamic
(PK/PD) analyses in a larger cohort of patients to develop an algorithm aiming at optimization of the sero-
therapy containing conditioning regimen.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation
(HSCT) is a curative therapy in children with a variety of
malignant diseases and nonmalignant diseases [1,2]. Still,
transplantation-related morbidity, particularly graft-versus-dgments on page 481.
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ty for Blood and Marrow Transplantation.host disease (GVHD), and recurrence of initial disease
remain the major causes of an unsuccessful outcome [3-5].
Before HSCT, patients are conditioned with chemo-
therapy, irradiation, and/or serotherapy to eliminate residual
malignant cells, prevent acute and chronic GVHD, and facil-
itate engraftment. Serotherapy usually consists of antithy-
mocyte globulin (ATG), a polyclonal antibody, or the
monoclonal antibody alemtuzumab. ATG is a polyclonal
immunoglobulin preparation obtained by immunization of
rabbits or horses with human thymocytes or T cell lines.
Alemtuzumab is a humanized monoclonal antibody speciﬁc
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used to eliminate T cells, but they also target other cell types,
eg, B cells and natural killer (NK) cells [6-10]. ATG and
alemtuzumab are considered instrumental in reducing the
risk of rejection by suppressing the reaction of host T cells
against the graft. However, because of their long half-lives,
the antibodies will usually remain present after trans-
plantation and eliminate the donor T cells infused with the
graft as well. In this way, these antibodies not only reduce the
occurrence of GVHD [5,7,11-13], but they may also have a
negative impact on the occurrence of a graft-versus-
leukemia effect [1,13]. Furthermore, the negative impact of
ATG and alemtuzumab on the recovery of lymphocytes after
HSCT is associated with an increased risk of viral infections/
reactivations [5,6,14-16]. Alemtuzumab has a longer half-life
(15 to 21 days) than ATG (4 to 14 days), leading to a more
prolonged effect on lymphocyte recovery [14,17-19].
Although ATG and alemtuzumab are frequently used in
pediatric stem cell transplantations, there are only a few
studies comparing the effects of ATG and alemtuzumab
exposure on the outcomes after transplantation in children.
In a large multi-center study in a cohort of children with
acute lymphoblastic leukemia after unrelated donor trans-
plantation, Veys et al. [5] showed that alemtuzumab was
more effective than ATG in lowering the risk of severe acute
GVHD, whereas serotherapy as such did not compromise
leukemia-free survival. Myers et al. [20] evaluated the inci-
dence of adenovirus infection in 111 pediatric recipients of
bonemarrow transplants with either ATG or alemtuzumab in
their conditioning regimen. Besides an increased risk of
adenovirus infection in alemtuzumab-treated patients, they
found no signiﬁcant differences in complications, eg, GVHD,
and overall survival between both serotherapy groups.
Shah et al. [13] compared 14 alemtuzumab-treated patients
with 13 ATG-treated patients after pediatric HSCT and
concluded that alemtuzumab is more effective than ATG in
decreasing the incidence of GVHDwithout increasing the risk
of relapse or infectious complications. They also evaluated
T cell recovery after transplantation and reported a signiﬁ-
cantly slower T cell recovery after alemtuzumab compared
with ATG. To our knowledge, other single-center studies
comparing the recovery of the different lymphocyte subsets
(T, B, and NK cells) in children after applying these 2 types of
serotherapy are lacking.
The aim of this study is to compare the effects of ATGwith
alemtuzumab as part of the conditioning regimen and to
evaluate the impact of the length of lympholytic exposure to
these drugs after HSCT on various outcome parameters after
allogeneic stem cell transplantation, ie, immune recovery,
GVHD, infections and survival, in children receiving HSCT as
part of the treatment of different benign and malignant
hematological diseases.METHODS
Patients
Between January 2003 and May 2012, 235 pediatric patients with ma-
lignant and benign hematological diseases received their ﬁrst HSCT at the
pediatric HSCT unit of Leiden University Medical Center (LUMC). All patients
who underwent transplantation with a bone marrow or peripheral blood
stem cell graft from an unrelated or matched family donor andwho received
serotherapy as part of their conditioning regimen and GVHD prophylaxis
after HSCT were eligible for this study. By applying these inclusion criteria,
patients receiving no serotherapy (n ¼ 48), a cord blood transplant (n ¼ 19),
a graft from a haploidentical donor (n ¼ 19), or those not receiving GVHD
prophylaxis (n ¼ 1) were excluded. Consequently, the ﬁnal study cohort
consisted of 148 patients. Analysis was performed using July 1, 2014 as the
cut-off date for follow-up.All data used for this study were obtained from the databases of the
pediatric HSCT unit at the LUMC and the European Bone Marrow Transplant
Group. The medical ethical committee of the LUMC approved this study
(P01.028). Informed consent was obtained from all patients included in the
study and/or their parents.Serotherapy
To determine the impact of the different types of serotherapy on various
outcome parameters, patientswere divided into 2 groups: (1) those receiving
ATG (Thymoglobulin; Genzyme, Naarden, the Netherlands) at an intended
cumulative dose of 10 mg/kg body weight (BW) divided over 3 to 5 days,
mostly starting at day 5; and (2) those receiving alemtuzumab (Campath;
Genzyme) at an intended cumulative dose of 1 mg/kg BW, divided over 3 to 5
days,mostly startingatday5. Steroids (prednisone2mg/kg, in4doses)were
given throughout the course of serotherapy, starting the evening before ﬁrst
dose of serotherapy, throughout the entire course of serotherapy. Over the
years, we changed the dose (from 1 to 2 mg/kg) and starting time of steroids
(from just before infusion to the day before infusion), which led to less ATG
infusionerelated side effects. Clemastine has always been given just before
the start of each infusion. Upon a systemic inﬂammatory reaction (ie, fever,
tachycardia, hypotension), additional steroids (200 mg/m2 hydrocortisone)
and clemastine were given.
In total, 15 patients showed a severe systemic reaction upon the ﬁrst
administration of ATG necessitating a switch to alemtuzumab. These
patients, receiving a median dose of 2.5 mg ATG/kg BW and of .6 mg
alemtuzumab/kg BW, were classiﬁed in the alemtuzumab group. Impor-
tantly, active ATG serum concentrations were already below the level of
detection, ie, <.1 arbitrary units (AU)/mL, at the time of HSCT in these
patients. Separate analysis of these “switchers” indicated that the outcomes,
including immune recovery, were comparable to those of the 23 children
only receiving alemtuzumab (see Supplementary Text S1).
Active ATG, the fraction of the product capable of binding to cells, and
alemtuzumab levels were measured using quantitative ﬂow cytometry
assays, both in modiﬁcations of the method described [12,18]. In short,
HUT-78 T cells were incubated with 4-fold dilutions of patients’ serum,
starting with a dilution of 1:8, followed by washing and incubation with
conjugated secondary antibodies; for active ATG, Alexa Fluor 647elabeled
goat anti-rabbit IgG (Life Technologies, Carlsbad, CA) and for alemtuzumab,
Alexa Fluor 647elabeled goat antihuman IgG (Life Technologies). To
construct a reference curve, HUT cells were incubated with known amounts
of ATG or alemtuzumab. Finally, cells were washed and analyzed by ﬂow
cytometry on a FACS Scan (Becton Dickinson Biosciences, Franklin Lakes, NJ).
Mean ﬂuorescence intensities obtained at the different standard dilutions
were plotted against the active ATG or alemtuzumab concentrations. Active
ATG is measured in AU. Five mg/mL ATG was arbitrarily set at containing an
active ATG concentration of 5000 AU/mL. The lower limit of detection for
active ATG was .1 AU/mL [12] and for alemtuzumab, .01 mg/mL.
Standard active ATG measuring was done from April 2004. Active
ATG levels were available for 102 of the 111 ATG-treated patients and
alemtuzumab levels were available for all 38 alemtuzumab-treated patients.Conditioning Regimen
Depending on their diagnosis and condition, patients received chemo-
or total body irradiationebased regimens. Transplantation procedures and
conditioning regimens were generally according to the European Group
for Blood and Marrow Transplantation recommendations for the various
underlying diseases. To investigate the impact of irradiation and chemo-
therapy, conditioning regimens were divided into 2 groups: (1) myeloa-
blative conditioning (MA) and (2) nonmyeloablative conditioning (NMA).
Any regimen containing high-targeted busulfan (above 65 to 100 mg/
hour/L), total body irradiation, or treosulfan combined with thiotepa were
considered MA. Low-targeted busulfan (45 to 65 mg/hour/L, cyclophos-
phamide with or without ﬂudarabine, or treosulfan with ﬂudarabine
(without thiotepa) were considered NMA or reduced intensity [21]. All
patients who received reduced-intensity conditioning regimens were
classiﬁed as NMA.Supportive Care
Standard care consisted of strict protective isolation and oral adminis-
tration of antimicrobial drugs for gut decontamination. No cytomegalovirus
(CMV), Epstein-Barr virus (EBV), or human adenovirus (HAdV) prophylaxis
were used. Viral loadmonitoring by PCRwas performed at least onceweekly
during the ﬁrst 8 weeks after transplantation and, thereafter, at each visit to
the outpatient clinic until the number of peripheral blood T cells exceeded
300 cells/mL. GVHD prophylaxis consisted of calcineurin inhibitor (CI;
cyclosporine [CsA] or tacrolimus in case of CsA intolerance) or a combination
of CI and methotrexate in almost all patients. Three patients received
L. Willemsen et al. / Biol Blood Marrow Transplant 21 (2015) 473e482 475additional mycophenolatemofetil (CellCept) or corticosteroids and 1 patient
received no GVHD prophylaxis.Donors
Stem cell sources used in this study consisted of bone marrow grafts and
peripheral blood stem cells from related or unrelated donors. All patients
and donors were typed using PCR high resolution typing for HLA class I and
II antigens (10 antigens: A, B, C, DRB, and DQB). HLA-matched donors were
deﬁned as 10 out of 10 matched.Table 1
Patient Characteristics (n ¼ 148)
Characteristic ATG Group Alemtuzumab
Group
P
Value
Patients, n 110 38
Patient age, median (range), yr 7.8 (.4-18.6) 13.3 (3.9-19.0) <.001
Patient sex .545
Male 74 (67) 28 (74)
Female 36 (33) 10 (26)
Diagnosis .180
Benign hematological disease 46 (42) 11 (29)
Malignant disease 64 (58) 27 (71)
Donor .430
Identical related donor 17 (15) 7 (18)
Other related donor 3 (3) 3 (8)
Unrelated donor 90 (82) 28 (74)
Donor-recipient HLA match 1.000
10 of 10 HLA match 72 (66) 25 (66)
1 or more HLA mismatch(es) 38 (34) 13 (34)
Graft type .455
Bone marrow 93 (85) 30 (79)
Peripheral blood stem cells 17 (15) 8 (21)
Graft manipulation <.001
No depletion 107 (97) 29 (76)
T celledepleted graft* 3 (3) 9 (24)
Conditioning regimeny <.001
MA 102 (92) 24 (63)
NMA 8 (8) 14 (37)
Nucleated cells infused, 108/kg,
(average  SEM)
Bone marrow 2.8  .2 2.1  .7 .17
Peripheral blood stem cells 14.6  3.0 12.5  4.6 .72
GVHD prophylaxis .001
CI 3 (3) 8 (21)
CI þ MTXz 107 (97) 30 (79)
CMV status .848
Recipient and/or donor
seropositive
67 (61) 22 (58)
Recipient and donor both
seronegative
43 (39) 16 (42)
EBV status .339
Recipient and/or donor
seropositive
104 (95) 38 (100)
Recipient and donor both
seronegative
6 (5) 0 (0)
Dosage serotherapy
Cumulative dose ATG, median
(range), mg/kg
10 (5-11)
Cumulative dose alemtuzumab,
median (range), mg/kg
.8 (.2-1.4)
Follow-up, median (range), mo
All patients 57 (2-135) 57 (0-138)
Survivors 66 (27-135) 112 (27-138)
CI includes cyclosporine or tacrolimus; MTX, methotrexate.
Data presented are n (%) unless otherwise indicated.
* Depletion either by negative selection (CD3 and CD19 depletion) or
positive selection (CD34 selection).
y Conditioning regimens that contained either high-dose total body
irradiation or high-dose busulfan or treosulfan were classiﬁed as MA
conditioning. All other regimens were classiﬁed as NMA conditioning
(cyclophosphamide alone or ﬂudarabine in combination with cyclophos-
phamide, thiotepa or melfalan) [21].
z Three patients received additional mycophenolate mofetil (CellCept) or
corticosteroids.Deﬁnitions
Cell reconstitution
The day of engraftment was deﬁned as the ﬁrst day of 2 consecutive
measurements at which an absolute neutrophil count of at least .5  109/L
was achieved in the absence of granulocyte infusion. Recovery of monocytes
and CD3þ T cells was deﬁned as the ﬁrst day of 2 consecutive measurements
with an absolute cell count of at least 100/mL. Recovery of CD3/CD4þ T cells,
CD3/CD8þ T cells, (CD3 CD56þ CD16þ/) NK cells, and (CD19/CD20þ) B cells
was deﬁned as the ﬁrst day of 2 consecutivemeasurements with an absolute
cell count of at least 50/mL for the respective cell (sub)population. Neutrophil
andmonocyte counts were obtained from hematological leukocyte counting
and differentiation, which was performed every 1 to 3 days during the ﬁrst
2 months after HSCT. T cell, T cell subsets, NK cell, and B cell analysis in
peripheral blood mononuclear cells (PBMC) was performed every week,
when sufﬁcient lymphocytes were present (usually from 2 to 3 weeks after
HSCT onward) by immunostaining and ﬂow cytometry (FACS Calibur II,
Becton Dickinson Biosciences). Data were analyzed using BD Cellquest
software. The progress of lymphocyte counts (T, B, and NK cells) was eval-
uated over time (1, 2, 3, 6, and 12 months after HSCT). All results on test
days closest to day 30, day 60, day 90, day 180, and day 365 were included
in these analyses of cell recovery. The effect of ATG and alemtuzumab
on naïve and memory/effector T cells was evaluated using absolute naïve
(CD45RAþCCR7þ) and memory/effector (CD45RA and/or CCR7) CD3/
CD4þ, and CD3/CD8þ T cell counts.
Length of lympholytic drug exposure
To investigate the impact of drug exposure on immune reconstitution,
the length of lympholytic drug exposure after transplantation was deter-
mined. For this purpose, the day after HSCT that the drug level fell below 1
AU/mL and .2 mg/mL was calculated for ATG and alemtuzumab, respectively.
Above this level, in none of the patients T cells recovered to  100 cells/mL
(Text S2 and Figure S1, supplementary data).
GVHD
Incidences of acute and chronic GVHD were classiﬁed using the
Glucksberg and Shulman criteria, respectively [22,23]. Acute and chronic
GVHD referred to all grades (I to IV and limited/extended, respectively),
whereas severe acute GVHD was deﬁned as grade II to IV acute GVHD.
Viral infection/reactivation
CMV, EBV, and HAdV infections/reactivations were deﬁned as 2
consecutive viral DNA loads of at least 1000 copies/mL in serum or plasma
samples separated by at least 3 days, determined with real time quantitative
(RQ) PCR in the ﬁrst 100 days after transplantation [24-27]. In these cases,
preemptive treatment with ganciclovir (CMV), rituximab (EBV), or cidofovir
(HAdV) was initiated. Pretransplantation CMV and EBV serostatus of patient
and donor were determined for all HSCT couples and only CMV and EBV-
seropositive patients and seronegative patients with a seropositive donor
(at risk patients) were included in CMV and EBV infection/reactivation an-
alyses, respectively.
Chimerism
Donor chimerism, analyzed in PBMC using the Powerplex 16 assay
(Promega, Leiden, the Netherlands [28]), was arbitrarily categorized as: (1)
donor chimerism of at least 95% and (2) less than 95%.
Survival
Overall survival (OS) was deﬁned as time to death, regardless of the
cause, or last follow-up (censoring). Event-free survival (EFS) referred to
the time to disease recurrence, retransplantation, death, or last follow-up
(censoring). Overall mortality and treatment failure were used as the
inverse of OS and EFS, respectively, in multivariate analysis. Nonrelapse
mortality (NRM) was deﬁned as death not related to recurrence or
progression of the original disease. Relapse referred to the incidence of
recurrence of malignant diseases. Only patients with malignant diseases
were included in relapse analysis.Statistical Analysis
All analyzed variables and outcomes were compared between the ATG
group and the alemtuzumab group. Differences in patient characteristics
among the treatment groups (Table 1) were compared using Mann-Whitney
rank tests for continuous data, chi-squared test for categorical data, and
Fisher’s exact tests for binomial data. The cumulative OS and EFS and the
cumulative incidence of NRM, relapse, GVHD, viral reactivations, and the
recovery of immune cells (neutrophils, monocytes, CD3, CD4, CD8, NK, and B
cells) were calculated using the Kaplan-Meier method. All were descriptive
values. The probabilities of OS, EFS NRM, relapse, GVHD, viral reactivations,
and recovery of immune cells were compared with log-rank tests.
Table 2
Median Day, Univariate, and Multivariate Analysis of Appearance of Various
Cell Subsets
Appearance of Cells,
Median Day (95% CI)*
Log
Rank
Multivariate
Analysisy
ATG Alemtuzumab P
Value
HR (95% CI) P
Value
Neutrophils 22 (20-24) 28 (26-30) .030 .67 (.40-1.14) .139
Monocytes 21 (20-22) 28 (22-34) .001 .53 (.31-.91) .022
CD3 T cells 29 (25-33) 98 (79-117) <.001 .35 (.20-.61) <.001
CD4 T cells 36 (32-40) 104 (93-115) <.001 .33 (.18-.60) <.001
CD8 T cells 34 (28-40) 114 (98-130) <.001 .35 (.19-.65) .001
NK cells 22 (21-23) 34 (30-38) <.001 .47 (.27-.82) .008
B cells 54 (50-58) 54 (49-59) .722 1.07 (.58-1.98) .819
95% CI indicates 95% conﬁdence interval.
* Median ﬁrst day of constitutive cell counts above .5  109/L for
neutrophils, above 100/mL for CD3 T cells and monocytes, and above
50/mL for CD4 T cells, CD8 T cells, CD3 CD56þ CD16þ/ NK cells and
CD19/CD20þ B cells.
y Cox proportional hazard regression models, corrected for age, patient
sex, conditioning regimen, graft manipulation, diagnosis, graft type, and
HLA match.
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using crosstabs and compared with chi-squared tests.
The effects of serotherapy and other covariates on OS, treatment failure,
NRM, relapse, GVHD, viral reactivations, and recovery of immune cells were
analyzed by Cox proportional hazard regression models. The effects on
chimerism were assessed using binary regression models. The effects on
immune cell counts (CD3, CD4, CD8, NK, and B cells) were analyzed using
linear mixed models (ﬁxed main effects), in which multiple comparisons at
different time points were taken into account.
The primary objective of this study was to compare ATG and alemtuzu-
mab. Therefore, serotherapy was included in all multivariate analyses and
ATG was set as reference category. Besides serotherapy, patient age, patient
sex (female versus male), diagnosis (malignant disease versus benign
hematological disease), conditioning regimen (MA versus NMA), graft
manipulation (T cell depletion versus no T cell depletion), graft type (bone
marrow versus peripheral blood stem cells), and HLAmatch (compete match
versus incomplete match) were included in all multivariate analyses using
the “enter” method. Other variables considered were relationship to donor,
ie, unrelated versus identical related or nonhaploidentical other related, age
of the donor, sex match between patient and donor (matched versus mis-
matched), CMV and EBV serostatus patient (seropositive versus seronega-
tive), CMV and EBV serostatus donor (seropositive versus seronegative),
GVHD prophylaxis (CI and methotrexate versus CI alone or no prophylaxis),
and year of transplantation (2003 to 2005, 2006 to 2008, or 2009 to 2012).
For all multivariate and univariate analyses, P values < .05 were
considered statistical signiﬁcant. All P values were 2-sided. For the evalua-
tion of viral reactivations and relapse, patients were censored at time of
retransplantation, death from any cause, or last follow-up. Additional
censoring was performed at time of relapse or donor lymphocyte infusion
for evaluation of cell reconstitution, chimerism, and GVHD. Patients who
died or underwent retransplantation within 100 days were excluded for
chronic GVHD analyses. Patients receiving rituximab (MabThera, Roche,
Basel, Switzerland), were excluded from B cell analyses from the ﬁrst time
point they received rituximab. In NRM analyses, patients were censored at
time of retransplantation, relapse, or last follow-up. Analyses were done
with SPSS20 software (IBM SPSS Inc., Chicago, IL). Graphs were made in
Prism Graphpad 6.02 (Graphpad Software, La Jolla, CA).RESULTS
Patient Characteristics
A total of 110 patients received ATG and 38 patients
received alemtuzumab as part of their conditioning regimen.
As shown in Table 1, there are some signiﬁcant differences in
patient characteristics between the 2 serotherapy groups.
Patients treated with alemtuzumab were older, more often
received a T celledepleted graft and CsA only as GVHD
prophylaxis, and were less likely to have a MA conditioning
regimen than those treated with ATG. These differences
between the 2 serotherapy groups did not bias the results
of the analyses of T cell recovery and overall mortality risk
(see section “Differences in Patient Characteristics between
Serotherapy Groups”).
Themedian total dose of ATGwas 10mg/kg (range, 5 to 11
mg/kg); 97% of the ATG recipients actually received a total
dose of 10mg/kg. Themedian total dose of alemtuzumabwas
.8 mg/kg (range, .2 to 1.4 mg/kg). The pretransplantation
clinical condition of the 38 alemtuzumab-treated patients
was not signiﬁcantly different from that of a subcohort of
ATG-treated patients matched with respect to original
disease, donor type, and year of HSCT (see Supplementary
Text S3). Regarding the various outcome parameters, the 15
ATG to alemtuzumab switchers did not differ signiﬁcantly
from the 23 children receiving alemtuzumab only (see
Supplementary Text S1).Engraftment and Monocyte Recovery
In total, 145 patients (98%) engrafted. The median time to
engraftment and to appearance of monocytes was shorter in
the ATG group compared with the alemtuzumab group
(Table 2). Multivariate analysis showed a trend to slowerengraftment and a signiﬁcant slower recovery of monocytes
after alemtuzumab (Table 2).
Immune Reconstitution
The median day of appearance of T cells in the ATG group
was 29 days for total CD3 T cells, 36 days for CD4, and 34
days for CD8 T cell subsets, whereas the recovery of T
cells was delayed in the alemtuzumab group (98 days for
CD3, P < .001; 104 days for CD4, P < .001; and 114 days for
CD8, P < .001) (Table 2). Multivariate analysis showed that
alemtuzumab was associated with a slower recovery of
CD3 T cells (hazard ratio [HR], .35; P < .001) (Table 2), CD4
T cells (HR, .33; P < .001), and CD8 T cells (HR, .35; P ¼ .001).
The recovery of NK cells was slower in alemtuzumab-
treated patients compared with in ATG-treated patients
(34 and 22 days, respectively; P < .001). This association
was also observed in multivariate analysis (HR, .47; P ¼ .008)
(Table 2). There was no difference in the median time to
appearance of B cells (54 days for both groups, Table 2)
between the ATG and alemtuzumab-treated patients.
To further evaluate the effect of serotherapy, lymphocyte
subset counts at 1, 2, 3, 6, and 12 months after HSCT were
compared between the ATG and alemtuzumab groups.
Signiﬁcant differences in T cells counts between the treat-
ment groups were observed during the ﬁrst 3 months after
HSCT (Figure 1). In the alemtuzumab group, CD3, CD4, and
CD8 T cell counts were lower in the ﬁrst 3 months after HSCT
compared with those of the ATG group (P ¼ .025 for CD4
T cell counts at 3 months and P  .001 for all others). NK
cell counts were signiﬁcantly lower in alemtuzumab-treated
patients 1 month after HSCT (P < .001) (Figure 1). No dif-
ferences in any of the T cell populations, NK cell, or B cell
counts were observed 6 and 12 months after HSCT.
Naïve and memory/effector CD4 and CD8 T cell counts
after HSCT were compared between both serotherapy
groups. Memory/effector CD4 and CD8 T cell were signiﬁ-
cantly higher after ATG (P < .001 for both) (Figure 2). No
difference was observed in naïve CD4 and CD8 T cells counts.
Impact of the Length of Lympholytic Drug Exposure on
Immune Reconstitution
Based on the length of lympholytic exposure to active
ATG after HSCT, ATG-treated patients were divided in 3
Figure 1. Recovery of lymphocyte subsets after transplantation. Geometric mean of total T cell (CD3), CD4 T cell subset, CD8 T cell subset, NK, and B cell counts at 1, 2,
3, 6, and 12 months after transplantation of patients who received ATG (black lines) and alemtuzumab (grey dashed lines). The grey shaded areas represent the range
of healthy children. Error bars indicate the lower and upper 95% CI of the geometric mean. Months after transplantation are shown on all x-axes. On all y-axes, values
represent cells/mL. Subset counts were compared using multivariate linear regression analyses with correction for age, patient sex, conditioning regimen, graft
manipulation, diagnosis, graft type, HLA match, CMV serostatus of the patient, and CMV serostatus of the donor. An asterisk indicates a signiﬁcant difference between
ATG and alemtuzumab-treated patients (P < .05). All patients receiving rituximab (MabThera), usually for EBV infections, were excluded from B cell analyses from the
moment they received Rituximab.
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lympholytic exposure was <10 days), “median exposure”
group (10 to 18 days), and “long exposure” group (18 days).
Alemtuzumab-treated patients were accordingly divided in 3
groups, with limits being 34 days, 35 to 48 days, and 48
days.
Figure 3 shows the recovery of neutrophils, monocytes,
and lymphocyte subsets for the different exposure groups
among the ATG-treated (Figure 3A) and the alemtuzumab-
treated (Figure 3B) patients. Multivariate analysis showed
that CD3, CD4, and CD8 Tcell recoverywas delayed inpatients
with long exposure compared with patients with short or
median exposure in the ATG-treated group (P¼ .001, P¼ .005,Figure 2. Naïve and memory/effector T cell counts. Absolute counts of naïve and me
received ATG (dark circles) and alemtuzumab (light grey triangles). Within the CD3/
CD45RAþCCR7þ and memory/effector cells as CD45RA and/or CCR7. The horizontal b
CI. Values on y-axes represent cells/mL. Cell counts were compared using multivariat
regimen, graft manipulation, diagnosis, graft type, HLA match, CMV serostatus of the
difference between ATG and alemtuzumab-treated patients (P < .05).and P ¼ .003, respectively). In contrast, NK cell recovery
tended to be slower inpatientswith short exposure compared
with those with long or median exposure (P ¼ .054). No
differenceswere observed in B cell, neutrophil, andmonocyte
recovery (P ¼ .619, P ¼ .683, and P ¼ .675, respectively).
In alemtuzumab-treated patients, similar effects of drug
exposure on T cell recovery were seen (Figure 3B). CD8 T cell
recovery was signiﬁcantly faster (P < .001) and CD3 T cell
recovery tended to be faster (P ¼ .125) in patients with short
alemtuzumab exposure compared with those with long or
median exposure. NK cell recovery was also faster in patients
with short alemtuzumab exposure (P ¼ .027). No differences
were observed in B cell, neutrophil, and monocyte recovery.mory/effector CD4 and CD8 T cell counts 2 months after HSCT of patients who
CD4þ and CD3/CD8þ T cell subsets naïve cells were phenotypically deﬁned as
lack lines and error bars indicate geometric mean and its lower and upper 95%
e linear regression analyses with correction for age, patient sex, conditioning
patient, and CMV serostatus of the donor. An asterisk indicates a signiﬁcant
Figure 3. Impact of drug exposure on immune recovery. Cumulative incidence of recovery of cell (sub)populations related to length of exposure to (A) ATG and (B)
alemtuzumab after HSCT. Recovery was deﬁned as reaching absolute cell counts above .5  109/L for neutrophils, above 100/mL for CD3 T cells and monocytes, and
above 50/mL for CD4 T cells, CD8 T cells, NK cells, and B cells. Patients were divided in 3 groups based on the length of lympholytic drug exposure: short exposure
(black lines), median exposure (grey dashed lines), and long exposure (grey dotted lines). Days after transplantation are shown on all x-axes.
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The incidence of any grade of acute GVHD (aGVHD) was
higher in the ATG group (P ¼ .030). In multivariate analysis,
the risks of aGVHD and severe aGVHD were lower in the
alemtuzumab group comparedwith the ATG group, although
not signiﬁcantly (HR, .34; P ¼ .175 and HR, .20; P ¼ .130,
respectively) (Table 3).
No differences were observed in the incidence and risk of
chronic GVHD (cGVHD) between the ATG group and the
alemtuzumab group (P ¼ .703 and P ¼ .758, respectively).
Viral Reactivations
No differences in CMV reactivations were observed in
univariate or multivariate analysis (Table 3). The incidence of
EBV reactivations was higher in ATG-treated patients (30%)
compared with alemtuzumab-treated patients (8%, P ¼ .011).
Multivariate analysis also showed a lower risk of EBV reac-
tivations in alemtuzumab-treated patients (HR, .23; P¼ .039)(Table 3). Whereas patients who received alemtuzumab
were less likely to have an EBV reactivation, their risk of
HAdV reactivation tended to be higher compared with
ATG-treated patients (HR, 3.56; P ¼ .103) (Table 3).Chimerism
The proportion of patients with95% donor chimerism in
PBMC was similar for the ATG group and the alemtuzumab
group early after transplantation (Table 4). In multivariate
analysis, which, among others, included correction for
diagnosis and conditioning regimen, no differences in donor
chimerism were observed 1 and 2 months after trans-
plantation between the 2 serotherapy groups (Table 4).
Alemtuzumab was associated with a signiﬁcant decrease of
the proportion of patients with95% donor chimerism 3 and
6 months after transplantation (HR, .17; P ¼ .042 and HR, .06;
P ¼ .037, respectively) (Table 4).
Table 3
Incidence, Univariate, and Multivariate Analysis of GVHD and Viral
Reactivations
Numbers/Total (%)* Log
Rank
Multivariate
Analysisy
ATG Alemtuzumab P
Value
HR (95% CI) P
Value
GVHD
aGVHD I-IV 28/110 (25) 3/38 (8) .030 .34 (.07-1.62) .175
aGVHD II-IV 17/110 (15) 2/38 (5) .119 .20 (.02-1.62) .130
cGVHD 10/97 (10) 3/26 (12) .703 .76 (.13-4.34) .758
Viral reactivations
CMVz 30/67 (45) 8/21 (38) .522 .78 (.30-2.04) .611
EBVx 31/104 (30) 3/38 (8) .011 .23 (.06-.93) .039
HAdV 9/110 (8) 5/38 (13) .367 3.56 (.78-16.3) .103
* Descriptive values: number of patients with the described condition/
total of evaluated patients (%).
y Cox proportional hazard regression models, corrected for age, patient
sex, conditioning regimen, graft manipulation, diagnosis, graft type, and
HLA match (and GVHD prophylaxis in case of GVHD analyses).
z Only CMV-seropositive patients and seronegative patients with a
seropositive donor were included in this analysis.
x Only EBV-seropositive patients and seronegative patients with a sero-
positive donor were included in this analysis.
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Overall mortality was 42% in the alemtuzumab group
versus 21% in the ATG group (P ¼ .003) (Figure 4A, Table 5).
Multivariate analysis also showed that alemtuzumab was
associated with a higher overall mortality risk than ATG (HR,
2.59; P ¼ .020) (Table 5).
Compared with the ATG group, EFS was lower in the
alemtuzumab group (P < .001) (Figure 4B). The risk of treat-
ment failure (relapse, death, or retransplantation; inverse of
EFS) was higher for patients who received alemtuzumab (HR,
3.14; P < .001) (Table 5). The probability of NRM was higher
for patients treated with alemtuzumab in univariate analysis
(P ¼ .018) (Figure 4C) but not in multivariate analysis (HR,
2.89; P¼ .138) (Table 5). Furthermore, the incidence of relapse
was higher in the alemtuzumab group (P ¼ .024) (Figure 4D).
Multivariate analysis also showed that alemtuzumab-treated
patients were more at risk to relapse compared with ATG-
treated patients (HR, 5.10; P ¼ .001) (Table 5).Table 4
Incidence, Univariate, and Multivariate analysis of Donor Chimerism
Numbers/Total (%)* Log Rank Multivariate Analysisy
ATG Alemtuzumab P Value HR (95% CI) P Value
1 Month 1.000 .43 (.10-1.77) .244
<95% 19 (17) 6 (18)
95% 90 (83) 27 (82)
2 Months 1.000 .34 (.04-2.81) .319
<95% 12 (12) 4 (13)
95% 90 (88) 27 (87)
3 Months .072 .17 (.03-.94) .042
<95% 15 (16) 8 (36)
95% 77 (84) 14 (64)
6 Months .050 .06 (.00-.84) .037
<95% 15 (18) 5 (45)
95% 69 (82) 6 (55)
12 Months .355 .11 (.08-1.53) .100
<95% 9 (13) 3 (27)
95% 61 (87) 8 (73)
* For each time point (1, 2, 3, 6, and 12 months) the distribution of pa-
tients who had a donor chimerism of at least 95% or less than 95% is shown.
y Binary regression models, corrected for age, patient sex, conditioning
regimen, graft manipulation, diagnosis, graft type, and HLA match.Differences in Patient Characteristics Between
Serotherapy Groups
As shown in Table 1, there are some differences in patient
characteristics between the 2 serotherapy groups. Patients
treated with alemtuzumab signiﬁcantly more often received
a T celledepleted graft, were less likely to have an MA condi-
tioning regimen, and were signiﬁcantly older than patients
treated with ATG. Therefore, we investigated whether these
3 characteristics introduced a possible bias. Excluding the
22 patients who received an NMA conditioning regimen,
alemtuzumab was still associated with a signiﬁcantly higher
overall mortality risk (HR, 2.30; P ¼ .049; n ¼ 126) in multi-
variate regression analysis. Similarly, when the 12 patients
with a T celledepleted graft were excluded, the overall
mortality risk remained signiﬁcantly higher in the alemtuzu-
mab group compared with the ATG group (HR, 3.00; P¼ .009;
n ¼ 136). The age of the patients in the ATG group ranged
from .4 to 18.6 years, whereas in the alemtuzumab group,
the youngest patient was 3.9 years old (Table 1). The overall
mortality risk remained signiﬁcantly higher in the alemtuzu-
mab group compared with the ATG group (HR, 3.03; P¼ .015;
n ¼ 116) after excluding all patients younger than 4 years.
The same was observed for T cell recovery. Alemtuzumab
was associated with a signiﬁcantly delayed T cell recovery
compared with ATG in the total cohort (Table 2), in the
subcohort with only MA conditioning regimens included, in
the subcohort with all T celledepleted grafts excluded, and in
the subcohort with all patients younger than 4 years
excluded (P  .002 for all [sub]cohorts).
DISCUSSION
In this study, the effect of ATG as part of the conditioning
regimen on clinical and immunological outcome parameters
after stem cell transplantation in children was compared
with alemtuzumab. Our results show that after HSCT, the
recovery of lymphocytes, ie, CD3 T cells, CD4, and CD8 T cell
subsets, and to a less extent NK cells, was signiﬁcantly
delayed after alemtuzumab treatment compared with after
ATG. In addition, length of lympholytic exposure to active
ATG or alemtuzumab after HSCT had an impact on the ki-
netics of immune recovery. Furthermore, our data show that
ATG was associated with a higher OS and EFS, lower relapse
risk, more EBV reactivations, and reached 95% donor
chimerism in a signiﬁcantly higher proportion of patients.
Patients treated with alemtuzumab showed a trend to a
lower incidence of acute GVHD andmore HAdV reactivations.
A similar differential effect of alemtuzumab and ATG on T
cell recovery as found in our study has been reported in
adults receiving allo-HSCT mainly after reduced-intensity
conditioning [14]. Shah et al. [13] studied the impact of
serotherapy on the incidence of severe GVHD in a small
cohort of children and reported a univariate signiﬁcantly
slower CD3 T cell recovery after alemtuzumab compared
with after ATG. To our knowledge, there are no other studies
that have compared the effects of ATG and alemtuzumab on
the recovery of the different lymphocyte subsets in children.
Alemtuzumab affected both naïve and memory/effector
CD4 and CD8 T cells, whereas ATG mostly affected naïve CD4
and CD8 T cells. This differential effect of ATG on T cell
differentiation stages was also reported by Bosch et al. [6]. No
studies are available for alemtuzumab.
Previously, it has been shown that both a higher dose of
ATG [29] and administration of ATG closer to the day of
transplantation [30] were associated with a slower T cell
recovery after HSCT. In the present study, we used the blood
Figure 4. Kaplan-Meier survival curves. Probability of (A) overall survival, (B) EFS, (C) NRM, and (D) relapse (risk of recurrence of malignant disease) after HSCT with
ATG (black lines) and alemtuzumab (grey dashed lines) as part of the conditioning regimen.
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the impact of the length of lympholytic exposure to these
antibodies on immune reconstitution. Our results show
that this determines the pace of CD3, CD4, and CD8 T cell
recovery. This result is concordant with data from Bosch et al.
[6], in which higher levels of active ATG 1 week and 1 month
after transplantation were associated with decreased CD4
and CD8 T cell counts in adults. In a recent publication on the
impact of ATG serum levels on acute and chronic GVHD,
Chawla et al. [31] also reported a signiﬁcant correlation be-
tween the decrease in active ATG level and the T cell countTable 5
Incidence, Univariate, and Multivariate Analysis of Overall Mortality, Treat-
ment Failure, NRM, and Relapse
Numbers/Total (%)* Log
Rank
Multivariate
Analysisy
ATG Alemtuzumab P
Value
HR (95% CI) P
Value
Overall
mortalityz
23/110 (21) 16/38 (42) .003 2.59 (1.16-5.75) .020
Treatment
failurex
39/110 (36) 25/38 (66) <.001 3.14 (1.66-5.95) <.001
NRM 7/110 (6) 6/38 (16) .018 2.89 (.71-11.77) .138
Relapsek 14/64 (22) 10/27 (37) .024 5.10 (1.95-13.37) .001
* Descriptive values: number of patients with described condition/total
evaluated patients (%).
y Cox proportional hazard regression models, corrected for age, patient
sex, conditioning regimen, graft manipulation, diagnosis, graft type, and
HLA match.
z Overall mortality (risk of death, regardless of the cause) is the inverse of
overall survival.
x Treatment failure (risk of relapse, retransplantation, or death) is the
inverse of EFS.
k Only patients with malignant diseases were included in relapse (risk of
recurrence of malignant disease) analyses.1 month after HSCT. Whereas longer ATG exposure corre-
lated with a slower T cell recovery, NK cell recovery was
faster in patients with long active ATG exposure in our
study. Bosch et al. reported increased NK cell counts at day 28
after HSCT in patients with higher ATG levels 1 week after
transplantation [6]. The reason for the faster NK cell recovery
after longer ATG exposure observed in this and our study
remains unclear, but might be related to favorable expansion
of NK cells in a T lymphopenic setting [32]. A direct effect of
ATG on NK cells cannot be excluded [33].
In the alemtuzumab group, longer drug exposure was
associated with delayed T cell and NK cell recovery. This is in
line with data from Juliusson et al. [17] showing that a higher
dose of alemtuzumab, subcutaneously administered to
adults receiving allogeneic HSCT after NMA conditioning,
correlated with lower CD4 and CD8 counts after HSCT.
Gärtner et al. [34] reported that infusion of a higher dose
of alemtuzumab was associated with a signiﬁcantly lower
increase of NK cell counts 1 month after transplantation,
which is concordant with our ﬁndings.
Our data are the ﬁrst to connect the level of lympholytic
drug exposure to immune recovery and outcome after HSCT
in children. We were able to show that longer lympholytic
drug exposure delayed T cell recovery in both ATG- and
alemtuzumab-treated patients. Our data suggest that the
length of lympholytic ATG exposure was not associated with
OS, EFS, NRM, and relapse (Figure S2, Supplementary Data).
Multivariate analysis showed a nonsigniﬁcant trend to less
severe aGVHD and more EBV reactivations after long ATG
exposure (Figure S2). These observations are comparable to
those recently published by Chawla et al., which showed in
adults an association of high levels of exposure to ATG with
a low incidence of acute (grade II to IV) and cGVHD and with
a high incidence of EBV post-transplantation lymphoproli-
ferative disorder. They reported no signiﬁcant associations
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associated death [31]. Our alemtuzumab group was too
small to determine the impact of exposure levels. Comparison
of the low exposure alemtuzumab subgroup with the high
exposure ATG subgroup showed no signiﬁcant difference in
recovery of the various cell population, but a higher incidence
of overall mortality, treatment failure, and relapse of malig-
nant diseasewas observed in the low exposure alemtuzumab
subgroup. (Tables S1 and S2, Supplementary Data).
T cell depletion with ATG or alemtuzumab is a commonly
used strategy for prevention of GVHD [5,7,16,35,36]. Our data
showed a nonsigniﬁcant lower incidence of aGVHD after
alemtuzumab. In multivariate analysis, the risks of aGVHD
and severe aGVHD were lower in the alemtuzumab group,
although not signiﬁcantly. This is in accordance with data
from a large multicenter study by Veys et al. [5] as well other
studies [13,37]. It is attractive to speculate that a reduced
alloreactivity after alemtuzumab treatment caused by the
strong delay of the recovery of naïve T cells as well as
memory/effector T cells may also explain the relatively high
proportion of patients with donor chimerism <95% in chil-
dren receiving this serotherapy.
In the present study, we found more EBV reactivations in
the ATG group than in the alemtuzumab group. On the other
hand, alemtuzumab-treated patients tended to be more at
risk for HAdV reactivations. The latter was supported by data
on HAdV infection and HAdV-related disease reported by
Myers et al. [20]. However, they did not observe a difference
in EBV infections between both serotherapy groups. On the
other hand, Cohen et al. reported in pediatric patients after
HSCT signiﬁcantly more EBV viremia after ATG compared
with after alemtuzumab treatment [38].
Although ATG and alemtuzumab are frequently used in
pediatric HSCT, there are only a few studies comparing the
effect of ATG and alemtuzumab on survival outcomes in
children [5,13,20]. In these studies, no signiﬁcant differences
in survival rates between ATG- and alemtuzumab-treated
patients were found. Our study is the ﬁrst in which signiﬁ-
cantly lower survival rates became apparent after alemtu-
zumab compared with after ATG treatment. Also, the risk of
treatment failure and relapse were signiﬁcantly higher in
alemtuzumab-treated patients. This is possibly related to
the delayed T cell recovery after an alemtuzumab-containing
conditioning regimen. Although alemtuzumab was associ-
ated with a lower incidence of aGVHD and slower T cell
recovery, treatment with alemtuzumab did not translate in
an overall higher incidence of viral reactivations. On the
other hand, sustained complete donor chimerism was
established in a lower proportion of alemtuzumab-treated
patients and they more often received a second HSCT pro-
cedure, a stem cell boost, or donor lymphocyte infusion to
enhance hematopoiesis, to increase donor chimerism, and
to support immune reconstitution, respectively (data not
shown). This indicates that alemtuzumab-treated patients
had more transplantation-related complications.
One of the limitations of the present study is the diversity
of the study population. Althoughwe performedmultivariate
analyses to determine the impact of serotherapy on different
outcome parameters using known prognostic factors, there
may still be yet undeﬁned factors that inﬂuence theprognosis.
Furthermore, this is a retrospective studyand, therefore,more
subjected to bias than a prospective randomized controlled
trial.
This is the ﬁrst single-center study in a large cohort of
children to investigate the impact of ATG and alemtuzumabon immune reconstitution and clinical outcomes using
multivariate regression analyses. Our data show that a con-
ditioning regimen containing alemtuzumab delays recovery
of CD3, CD4, CD8 T, cells and NK cells compared with a
regimen containing ATG. This translated into a lower inci-
dence of aGVHD but also into higher risks of overall mortality,
treatment failure, and relapse of the original disease in chil-
dren with different benign and malignant diseases. Despite
these results, the use of alemtuzumab is still recommended in
patients who received ATG treatment before because of the
risks of sensitization and antibody formation against ATG
[12,39]. Our data are also the ﬁrst to connect the length of
lympholytic drug exposure to immune recovery and outcome
afterHSCT in children: longer drug exposure delayed the Tcell
recovery in both ATG- and alemtuzumab-treated patients.
Detailed pharmacokinetic/pharmacodynamic (PK/PD) ana-
lyses in a large cohort of patients are needed to develop an
algorithm aiming at optimizing the serotherapy-containing
conditioning regimen for individual patients.
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